Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024
See more here:
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
Recommendation and review posted by G. Smith
